Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells

Meindert Crop, Carla Baan, Sander Korevaar, J.N.M. IJzermans, Mario Pescatori, Andrew Stubbs, Wilfred van Ijcken, MH Dahlke, E Eggenhofer, Willem Weimar, Martin Hoogduijn

Research output: Contribution to journalArticleAcademicpeer-review

193 Citations (Scopus)


P>There is emerging interest in the application of mesenchymal stem cells (MSC) for the prevention and treatment of autoimmune diseases, graft-versus-host disease and allograft rejection. It is, however, unknown how inflammatory conditions affect phenotype and function of MSC. Adipose tissue-derived mesenchymal stem cells (ASC) were cultured with alloactivated peripheral blood mononuclear cells (PBMC) (mixed lymphocyte reaction: MLR), with proinflammatory cytokines [interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and interleukin (IL)-6] or under control conditions, and their full genome expression and function examined. Proinflammatory cytokines mainly increased indoleamine-2,3-dioxygenase expression, whereas ASC cultured with MLR showed increased expression of COX-2, involved in prostaglandin E-2 production. Both conditions had a stimulatory, but differential, effect on the expression of proinflammatory cytokines and chemokines, while the expression of fibrotic factors was decreased only in response to proinflammatory cytokines. Functional analysis demonstrated that inflammatory conditions affected morphology and proliferation of ASC, while their differentiation capacity and production of trophic factors was unaffected. The immunosuppressive capacity of ASC was enhanced strongly under inflammatory conditions. In conclusion, ASC showed enhanced immunosuppressive capacity under inflammatory conditions, while their differentiation capacity was preserved. Therefore, in vitro preconditioning provides ASC with improved properties for immediate clinical immune therapy.
Original languageUndefined/Unknown
Pages (from-to)474-486
Number of pages13
JournalClinical & Experimental Immunology
Issue number3
Publication statusPublished - 2010

Research programs

  • EMC MGC-02-02-01
  • EMC MGC-02-13-02
  • EMC MM-04-39-05
  • EMC MM-04-47-07

Cite this